Cerebrolysin
FPF-1070
Popular for:Neuroprotection, stroke recovery, dementia, TBI
42
Registered Trials
91
Trial Publications
624
PubMed References
Approved
Evidence Level
Overview
Cerebrolysin is a peptide preparation derived from purified porcine brain tissue, containing a mixture of neurotrophic peptides and amino acids. The short version: people usually care about it for neuroprotection, stroke recovery, dementia, tbi, but the strength of the evidence depends heavily on indication and study type.
Cerebrolysin is a peptide preparation derived from purified porcine brain tissue, containing a mixture of neurotrophic peptides and amino acids. It has been approved as a pharmaceutical in over 40 countries (primarily in Europe, Asia, and Latin America) for the treatment of stroke, traumatic brain injury, and dementia.
Developed by EBEWE Pharma (now part of EVER Pharma) in Austria, Cerebrolysin has been studied in numerous clinical trials involving thousands of patients. It is one of the few peptide-based neurotherapeutics with extensive human clinical data, though it is not FDA-approved in the United States.
Research Snapshot
What the evidence says
ApprovedCerebrolysin currently shows 42 registered trials from ClinicalTrials.gov, 91 PubMed trial publications (63 RCT-tagged), and 624 PubMed references matching the stored source query. Treat PubMed references as literature surface area, not a count of clinical trials.
Known vs uncertain
Known signals
- 42 registered trials are tracked from ClinicalTrials.gov intervention records.
- 91 PubMed clinical-trial publications are indexed.
- 63 PubMed randomized controlled trial publications are indexed.
- 624 PubMed references are tracked separately from trial counts and can include animal, in-vitro, review, mechanism, or clinical records.
Open questions
- Evidence strength may vary by indication, route, formulation, and population.
- Public anecdotes can highlight interest or concern but do not establish clinical efficacy.
- Regulatory status and compounding access can change independently from the research literature.
Mechanism of Action
Cerebrolysin contains low-molecular-weight peptides that mimic the effects of naturally occurring neurotrophic factors including BDNF, GDNF, NGF, and CNTF.
Key Research Benefits
Clinical Evidence Summary
Research Pipeline
International Regulatory Status
42
Registered Trials
91
Trial Publications
63
RCT Publications
624
PubMed References
Registered trials are ClinicalTrials.gov intervention records. Trial publications are PubMed records tagged as clinical trials or randomized controlled trials. PubMed references are broader source-query matches and can include animal studies, in-vitro work, reviews, mechanism papers, and trial publications.
42
Registered trials
91
Trial publications
63
RCT publications
624
PubMed references
95
Reviews
19
Meta-analyses
Registered trials source
Jun 1, 2026
Cerebrolysin
Uses the exact compound name as a ClinicalTrials.gov intervention query.
View sourceApproved in 40+ countries (Europe, Asia, Latin America). NOT FDA-approved in the US. Available as pharmaceutical in approved countries, research compound in US.
Key PubMed References
624 PubMed references · showing top 25 by relevance
View all on PubMedCerebroprotection in acute ischemic stroke: Perspectives on combining cerebrolysin with recanalization therapy.
Ribó M, Staszewski J, Zeiler SR, et al. · Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2026
PMID: 41349847Combined citicoline and Cerebrolysin for neuroprotection in traumatic brain injury: a retrospective cohort analysis.
Schlager P, Grgac I, Herzer G, et al. · Frontiers in neurology · 2025
PMID: 41409218C-REGS2-A multinational, high-quality comparative effectiveness study of Cerebrolysin in moderate acute ischemic stroke.
Vosko MR, Sanak D, Do Y, et al. · International journal of stroke : official journal of the International Stroke Society · 2025
PMID: 40851188Speech Therapy Combined With Cerebrolysin in Enhancing Nonfluent Aphasia Recovery After Acute Ischemic Stroke: ESCAS Randomized Pilot Study.
Homberg V, Jianu DC, Stan A, et al. · Stroke · 2025
PMID: 39957612Effects of cerebrolysin on behavioral changes and the tryptophan-kynurenine pathway in the prefrontal cortex of male mice in the ketamine model of schizophrenia.
Mafikandi V, Hosseini L, Seyedaghamiri F, et al. · Molecular biology reports · 2025
PMID: 40668305Anecdotes & Sentiment
This section summarizes what people are talking about in public sources. It can be useful for spotting questions, hype cycles, and recurring concerns, but it is separate from the evidence sections above.
No curated public-discussion themes are live for Cerebrolysin yet.
Side Effects & Safety
- Dizziness - Headache - Injection site reactions - Agitation or insomnia (uncommon) - Nausea - Must be administered IM or IV (no oral formulation)
Known Interactions
No curated interaction entry is live for Cerebrolysin yet.
Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.
Comparison Pages
Comparison pages
AllNo comparison page is linked yet.
Frequently Asked Questions
Research Disclaimer
This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Regulatory status can vary by compound, formulation, indication, and jurisdiction. Check official labeling, registry records, and qualified professional guidance before making any health-related decision. The studies referenced are linked to their original PubMed sources for verification.